Analysis of the ovarian (infundibulopelvic) ligament removed during ovarian cancer surgery
Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer
This project will test whether cancer in the infundibulopelvic ligament removed at surgery is linked to para‑aortic lymph node spread and outcomes in people with epithelial ovarian cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Complejo Hospitalario Universitario Insular Materno Infantil Academic / other |
| Locations | 1 site (Las Palmas de Gran Canaria) |
| Trial ID | NCT07100288 on ClinicalTrials.gov |
What this trial studies
This is an observational pathology study that examines infundibulopelvic ligament tissue resected as part of complete staging surgery in patients with epithelial ovarian cancer. Researchers will analyze the ligament specimens for tumor involvement and correlate those findings with para‑aortic lymph node status and patient outcomes. Eligible patients include those undergoing primary or interval complete staging surgery (hysterectomy, bilateral salpingo‑oophorectomy, pelvic and para‑aortic lymphadenectomy, omentectomy) with no residual disease and ECOG 0–1. The goal is to determine whether ligament involvement is associated with metastatic spread and survival.
Who should consider this trial
Good fit: People with epithelial ovarian cancer (including serous, endometrioid, mucinous, and carcinosarcoma) FIGO 2014 stage IA–IVB who undergo complete primary or interval staging surgery with no residual disease and have ECOG 0–1 are ideal candidates.
Not a fit: Patients with non‑epithelial ovarian tumors, ECOG 2–4, incomplete staging or residual disease after cytoreduction, or those who do not have the ligament resected are unlikely to benefit from this analysis.
Why it matters
Potential benefit: If ligament involvement predicts nodal spread or worse outcomes, findings could help clinicians improve staging and tailor surgical or adjuvant management.
How similar studies have performed: Some prior pathology series have reported that infundibulopelvic ligament involvement correlates with para‑aortic node metastasis and poorer survival, but the evidence remains limited and not widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ◦ Patients with epithelial ovarian cancer, including high- and low-grade serous, high- and low-grade endometrioid, mucinous (expansile and infiltrative types), and carcinosarcoma. * FIGO 2014 stage IA-IVB. * Patients undergoing primary surgery or interval surgery after 3-4 or 6 cycles of chemtherapy * Patients with no residual disease after surgery. * Patients with ECOG performance status 0-1. Exclusion Criteria: * ◦ Patients without epithelial ovarian cancer. * Patients with ECOG 2-4. * Patients who do not consent to participate in the study. * Patients who did not undergo complete staging surgery (including hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and omentectomy) or with residual disease after cytoreductive surgery.
Where this trial is running
Las Palmas de Gran Canaria
- Complejo Universitario Insular Materno Infantil de Las Palmas — Las Palmas de Gran Canaria, Spain (Recruiting)
Study contacts
- Study coordinator: beatriz NAVARRO SANTANA, pHD
- Email: bea_0904@hotmail.com
- Phone: +34620151146
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.